Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim Y-S, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr M-B, for the MODIFY I and MODIFY II Investigators.
Bezlotoxumab for prevention of recurrent Clostridium difficile infection.
N Engl J Med 2017;376:305-17. [Ref.ID 101394]